Dr. Viraj Lavingia holds a special interest in GI Oncology, especially colorectal cancers and pancreaticobiliary cancers.
He has so far handled more than 5000 cases.
Dr. Viraj won a scholarship award (UICC fellowship from City of Hope, Duarte USA, June 2016) for the project “HAI (Hepatic Arterial Infusion) chemotherapy for liver-limited metastatic colorectal cancer”.
He is a trained and certified member of the European Society for Medical Oncology & the American Society of Clinical Oncology.
Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review. (2016) Journal of gastrointestinal oncology, 7(6), E98.
Systemic treatment for metastatic colorectal cancer in the era of precision medicine (Journal of Surgical Oncology 2019-04).
Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review (Journal of Gastrointestinal Oncology 2016-12).
Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on Sunitinib (Indian Journal of Cancer 2016).
PRES, the most uncommon side effect of one of the commonest chemotherapy regimen, FOLFOX (Apollo Medicine 2015-03).
HCG - The Specialist in Cancer Care, India’s largest provider of cancer care, is at the forefront of the battle against cancer. Through its network of 24 comprehensive cancer centers, spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.